1. Inicio
  2. Publicaciones
  3. Biochemical assessment of metabolic associated fatty liver disease

Biochemical assessment of metabolic associated fatty liver disease

Fecha de publicación: Fecha Ahead of Print:

Autores de IDIVAL

  • Armando Raul Guerra Ruiz

    Autor

  • Paula Iruzubieta Coz

    Autor

  • Javier Crespo García

    Autor

Autores ajenos al IDIVAL

  • Casals, G
  • Lalana, M
  • Leis, A
  • Lopez, RM
  • Morales-Ruiz, M

Unidades

Abstract

Metabolic-associated fatty liver disease (MAFLD) is defined as fat accumulation in the liver in the presence of metabolic alterations. This disorder is generally asymptomatic and may progress to severe liver disease, which are linked to inflammation and/or fibrosis. MAFLD has a high prevalence (26%) and therefore a considerable number of patients are at high risk of having advanced liver disease. This document provides an overview of the most relevant serological markers in the characterization and diagnosis of MAFLD. An example is provided of a routine diagnostic algorithm that incorporates serological testing. A range of useful serological scores are currently available for the management of MAFLD patients, especially for the stratification of patients at risk of fibrosis. A large proportion of the population is at risk of developing severe liver disease. The integration of non-invasive serological markers in the stratification of patients at risk for liver fibrosis may contribute to improve the control and management of MAFLD patients.

© 2021 Armando R. Guerra-Ruiz et al., published by De Gruyter, Berlin/Boston.

Datos de la publicación

ISSN/ISSNe:
2628-491X, 2628-491X

Advances In Laboratory Medicine-Avances En Medicina De Laboratorio  WALTER DE GRUYTER GMBH

Tipo:
Article
Páginas:
199-208
PubMed:
37363330

Citas Recibidas en Web of Science: 7

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • hepatic steatosis; liver fibrosis; metabolic-associated fatty liver disease; serum markers; steatohepatitis

Financiación

Carlos III Health Institute (PI19/00774)
INSTITUTO DE SALUD CARLOS III. (PI15/02138)
INSTITUTO DE SALUD CARLOS III. (PI18/01304)
Spanish Ministry of Economy and Competitiveness (PID2019-105502RB-I00 a MM-R))

Proyectos asociados

Disfunción endotelial, ateromatosis subclínica y miocardiopatía en pacientes con infección por VHC. Caracterización y potencial reversibilidad con agentes antivirales directos.

Investigador Principal: Javier Crespo García

PI15/02138 . INSTITUTO DE SALUD CARLOS III. . 2016

Esteatohepatitis no alcohólica como enfermedad inflamatoria inmunomediada. Prevalencia y caracterización. Estudio INSTInCT

Investigador Principal: Javier Crespo García

PI18/01304 . INSTITUTO DE SALUD CARLOS III. . 2019

Compartir